Publication | Closed Access

A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer

Esophageal CancerPhase IiAkt Inhibitor IpatasertibGastrointestinal OncologyMedicinePharmacologyGastroenterologyPathologyCancer TreatmentOncologyRadiation OncologyGastroesophageal Junction Cancer